Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Alexis Musacchio Lasa

Osvaldo Reyes Acosta

Glay Chinea Santiago

Osmany Guirola Cruz

Vivian Huerta Galindo

Noralvis Fleitas Salazar

Julio Raul Fernandez Masso

Alejandro Miguel Martin Dunn

Patricia Gabriela Toledo Mayora

Rolando Eduardo Rodriguez Fernandez

Roberto Vera Alvarez

Ania De La Nuez Veulens

Yuliet Mazola Reyes

Vladimir Armando Besada Perez

Gerardo Enrique Guillen Nieto

Mario Pablo Estrada Garcia

Jorge Amador Berlanga Acosta

Boris Ernesto Acevedo Castro

Diana Garcia Del Barco Herrera

Raimundo Ubieta Gómez

Hilda Elisa Garay Perez

Silvio Ernesto Perea Rodriguez

Maribel Guerra Vallespi

Jeovanis Gil Valdés

Hilda Elisa Garay Pérez

Vivian Morera Cordova

Ania Cabrales Rico

Anabel Alvarez Acosta

Aniel Sánchez Puente

Rebeca Martinez Rodriguez

Pedro Antonio Lopez Saura

Mónica Sarría Núñez

Gabriel Ramon Padron Palomares

Jesus A Del Valle Rosales

Brizaida Maylin Oliva Argüelles

Julio R Maso

Silian C Leon

Alexey Llopiz Arzuaga

Gilberto Lazaro Pardo Andreu

Luis Javier Gonzalez Lopez

Santiago Duenas Carrera

Maribel Guerra Valespi

Juan Morales Grillo

Liz Alvarez-Lajonchere Ponce De Leon

Nancy Pavon Fuentes

Rolando Pajon Feyt

Ariel Vina Rodriguez

Jeovanis Gil Valdes

Julio C Alvarez Obregon

Nelson Acosta Rivero

Brizaida Maylin Oliva Arguelles

Gillian Martinez Donato

Giselle Penton Rol

Javier Marin Prida

Olvaldo Reyes Acosta

Efrain Rodriguez Jimenez

Anìa Cabrales Rico

Monica Sarria Nunez

Aniel Sanchez Puente

Sonia G Blanco

Julio Raúl Fernández Massó

Evelin C Menendez

Edelgis C Rodriquez

Selman H Sosa

Silva Rodriquez

Saturnino H Martinez

Guillen Nieto

Juan M Grillo

Lidia I Perez

Beatriz T Santos

Eduardo Penton Arias

Vladimir Armando Besada PÉREZ

Luis Javier GONZÁLEZ LÓPEZ

Javier MARÍN Prida

Eduardo PENTÓN Arias

Nancy PAVÓN Fuentes

Gerardo Enrique GUILLÉN Nieto

Gilberto Lázaro Pardo Andreu

Efraín RODRÍGUEZ JIMÉNEZ

Pedro Antonio LÓPEZ Saura

Mónica SARRÍA NÚÑEZ

Gabriel Ramón PADRÓN Palomares

Hilda Elisa Garay PÉREZ

Alejandro Miguel MARTÍN Dunn

Maribel Guerra VallespÍ

Jeovanis Gil VALDÉS

Brizaida Maylin Oliva ARGÜELLES

Julio Raúl FERNÁNDEZ MassÓ

Raimundo Ubieta GÓMEZ

Silvio Ernesto Perea RODRÍGUEZ

Liz Alvarez-Lajonchere Ponce De LEÓN

Santiago c/o Centro De Ingenieria Genética Y Biotecnologia DUEÑAS Carrera

The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.

Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases

This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.

Cancer therapy method

Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.

Antineoplastic compounds and pharmaceutical compositions thereof

Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions. The invention also comprises the use of such pharmaceutical compositions for prophylactic and/or therapeutic treatment of infection caused by all four serotypes of Dengue virus and other flaviviruses.

[object Object]

Formulation of vaccine antigens, containing as main components: a&#x2014;) one or several DNA expressing one or several proteins in the immunized individuals and b&#x2014;) a viral antigen, in appropriate proportions. Development of new formulations, minimizing the number of components that enhance and diversify the spectrum of immune response against different pathogenic entities and generating combined vaccines against pathogens. These formulations can be applied in the pharmaceutical industry for preventive and-or therapeutic use in human.

Vaccine formulation potentiated by the combination of DNA and an antigen

The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.

Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family

The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.

Method to block the infection by flaviviruses, molecules and uses

Peptidic chemical compounds obtained by in silico molecular modelling, having a structure that enables them to perform the same functions of peptidic growth hormone secretagogues. The invention also comprises the preparations containing such compounds and the use in medicines, food additives, nutritional supplements or other formulations of human or animal use.

Peptidic growth hormone secretagogues analog compounds and preparations thereof

The present invention is concerned with a method for the isolation of a nucleotide sequence which codes for a protein having a molecular weight of about 64,000 daltons, which is located on the outer membrane of N. meningitidis, as well as with the recombinant DNA obtained therefrom, which is used for the transformation of a host microorganism. The technical object pursued with the invention is the identification of a nucleotide sequence coding for a highly conserved and common protein for the majority of pathogenic Neisseria strains, the production of this protein with a high level of purity and in commercially useful amounts using the recombinant way, so that it can be used in diagnostic methods and vaccine preparations with a broad immunoprotection spectrum.

Nucleotide sequence coding for an outer membrane protein from Neisseria

Growing community of inventors

Havana, Cuba

Alexis Musacchio Lasa